New Company Joins With RPR To Develop Intrabody Technology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new company formed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute, has joined the Rhône-Poulenc Rorer Gencell network to help accelerate the development of its innovate intrabody, or intracellular antibody, technology.

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new companyformed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute,has joined the Rhône-Poulenc Rorer Gencell network to helpaccelerate the development of its innovate intrabody, or intracellularantibody, technology.

An intrabody is an engineered human antibody that works insidea cell, offering the potential for blocking molecular changesthat can lead to dis-eases such as cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.